Previous close | 1.3200 |
Open | 1.3600 |
Bid | 1.2500 x 800 |
Ask | 1.4900 x 1000 |
Day's range | 1.3000 - 1.4000 |
52-week range | 1.2500 - 15.0800 |
Volume | |
Avg. volume | 123,311 |
Market cap | 31.95M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.
Spruce Biosciences, Inc. (SPRB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Spruce Biosciences is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.